In the case of the VAV1 mRNA, we found a significant downmodulation in a small subgroup of samples derived from patients affected by diffuse large B–cell lymphoma (Figure 6A, Table 2), chronic lymphocytic leukemia (Table 2), and acute myeloid leukemia (Table 2). This evidence concerns the gene VAV1 and B-cell chronic lymphocytic leukemia.